English

Annual General Meeting of BioGaia

Report this content

The Annual General Meeting of BioGaia AB (publ) on 7 May 2020 voted, among other things, to approve the following resolutions:

  • adoption of the Annual Report
  • discharge from liability for the Board members and the Chief Executive Officer 
  • a dividend of SEK 3.75 per share and a grant of SEK 2.8 million to “The Foundation to Prevent Antibiotic Resistance” that was founded by BioGaia in 2017. The purpose of the Foundation is to reduce antibiotic resistance through support to research, education and information activities that promote the use of products and methods that prevent infections and therefore reduce the use of antibiotics and the risk of antibiotic resistance.
  • the number of Board members shall be seven without deputies
  • re-election of Ewa Björling, David Dangoor, Peter Elving, Anthon Jahreskog and Peter Rothschild and new election of Maryam Ghahremani and Vanessa Rothschild as Board members
  • re-election of Peter Rothschild as Board Chairman and David Dangoor as Deputy Board Chairman
  • re-election of the registered accounting firm Deloitte AB
  • Board member remuneration in an amount of SEK 650,000 to the Chairman, SEK 450,000 to the Deputy Board Chairman, SEK 250,000 to each of the other Board members elected by the general meeting, SEK 100,000 to the Chairman of the audit committee and SEK 50,000 each to the other members of the audit committee and SEK 40,000 to the Chairman of the remuneration committee and SEK 20,000 each to the other members of the remuneration committee 
  • an additional, monthly remuneration of not more than SEK 75,000 to the Chairman of the Board for duties in addition to the assignment as Chairman of the Board. The payment of any such additional remuneration shall be agreed upon in writing and further resolved upon by the Board
  • auditors’ fee shall be paid according to approved account
  • on a nominating committee in accordance with the nominating committee’s proposal
  • on principles for remuneration to senior executives in accordance with the Board’s proposal
  • on an authorization for the Board to resolve on new share issues in accordance with the Board’s proposal, and
  • on minor amendments to the articles of association in accordance with the Board’s proposal due to legislative changes

For additional information please contact
Isabelle Ducellier, Chief Executive Officer, BioGaia, telephone: +46 8 555 293 00

BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com

Subscribe

Documents & Links